JP7595567B2 - 抗ｆｇｆｒ２抗体製剤 - Google Patents

抗ｆｇｆｒ２抗体製剤 Download PDF

Info

Publication number
JP7595567B2
JP7595567B2 JP2021517575A JP2021517575A JP7595567B2 JP 7595567 B2 JP7595567 B2 JP 7595567B2 JP 2021517575 A JP2021517575 A JP 2021517575A JP 2021517575 A JP2021517575 A JP 2021517575A JP 7595567 B2 JP7595567 B2 JP 7595567B2
Authority
JP
Japan
Prior art keywords
antibody
fgfr2
formulation
histidine
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503886A (ja
JP2022503886A5 (cg-RX-API-DMAC10.html
Inventor
イサイアス プラド，
チン－イー ホアン，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2022503886A publication Critical patent/JP2022503886A/ja
Publication of JP2022503886A5 publication Critical patent/JP2022503886A5/ja
Priority to JP2024098544A priority Critical patent/JP2024138284A/ja
Application granted granted Critical
Publication of JP7595567B2 publication Critical patent/JP7595567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021517575A 2018-10-05 2019-10-04 抗ｆｇｆｒ２抗体製剤 Active JP7595567B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098544A JP2024138284A (ja) 2018-10-05 2024-06-19 抗ｆｇｆｒ２抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741772P 2018-10-05 2018-10-05
US62/741,772 2018-10-05
PCT/US2019/054684 WO2020072896A1 (en) 2018-10-05 2019-10-04 Anti-fgfr2 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098544A Division JP2024138284A (ja) 2018-10-05 2024-06-19 抗ｆｇｆｒ２抗体製剤

Publications (3)

Publication Number Publication Date
JP2022503886A JP2022503886A (ja) 2022-01-12
JP2022503886A5 JP2022503886A5 (cg-RX-API-DMAC10.html) 2022-09-29
JP7595567B2 true JP7595567B2 (ja) 2024-12-06

Family

ID=68343457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517575A Active JP7595567B2 (ja) 2018-10-05 2019-10-04 抗ｆｇｆｒ２抗体製剤
JP2024098544A Pending JP2024138284A (ja) 2018-10-05 2024-06-19 抗ｆｇｆｒ２抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098544A Pending JP2024138284A (ja) 2018-10-05 2024-06-19 抗ｆｇｆｒ２抗体製剤

Country Status (20)

Country Link
US (1) US20220010020A1 (cg-RX-API-DMAC10.html)
EP (1) EP3860563A1 (cg-RX-API-DMAC10.html)
JP (2) JP7595567B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210074286A (cg-RX-API-DMAC10.html)
CN (1) CN112804989A (cg-RX-API-DMAC10.html)
AU (1) AU2019355995B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021005204A2 (cg-RX-API-DMAC10.html)
CA (1) CA3112215A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021004985A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210217A (cg-RX-API-DMAC10.html)
EA (1) EA202190878A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21031139A (cg-RX-API-DMAC10.html)
IL (1) IL281976A (cg-RX-API-DMAC10.html)
MX (1) MX2021003766A (cg-RX-API-DMAC10.html)
MY (1) MY208925A (cg-RX-API-DMAC10.html)
PE (1) PE20211213A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021550670A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202102875YA (cg-RX-API-DMAC10.html)
UA (1) UA130250C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020072896A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4273166A4 (en) * 2020-12-29 2025-04-16 Shenzhen Forward Pharmaceuticals Co., Limited ANTI-FGFR2 ANTIBODIES AND USE THEREOF
TW202342527A (zh) * 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
AU2023243773A1 (en) * 2022-03-28 2024-10-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Novel anti-fgfr2 antibodies.
WO2024199362A1 (en) * 2023-03-31 2024-10-03 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Novel anti-FGFR2 antibodies
EP4786494A1 (en) * 2023-09-28 2026-08-05 Nanjing Leads Biolabs Co., Ltd. Anti-fgfr2 antibody and multispecific binding molecule comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527273A (ja) 2013-08-01 2016-09-08 ファイヴ プライム セラピューティクス インク アフコシル化された抗ｆｇｆｒ２ｉｉｉｂ抗体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527273A (ja) 2013-08-01 2016-09-08 ファイヴ プライム セラピューティクス インク アフコシル化された抗ｆｇｆｒ２ｉｉｉｂ抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEVEN J. SHIRE，FORMULATION OF PROTEINS AND MONOCLONAL ANTIBODIES (MABS)，MONOCLONAL ANTIBODIES，2015年，PAGE(S):93-120，https://doi.org/10.1016/B978-0-08-100296-4.00004-X
SUSUMU UCHIYAMA; ET AL，LIQUID FORMULATION FOR ANTIBODY DRUGS，BIOCHIMICA ET BIOPHYSICA ACTA，ELSEVIER，2014年08月13日，VOL:1884, NR:11，PAGE(S):2041-2052，https://doi.org/10.1016/j.bbapap.2014.07.016

Also Published As

Publication number Publication date
WO2020072896A1 (en) 2020-04-09
EP3860563A1 (en) 2021-08-11
IL281976A (en) 2021-05-31
UA130250C2 (uk) 2025-12-31
CR20210217A (es) 2021-06-18
JP2022503886A (ja) 2022-01-12
AU2019355995B2 (en) 2026-04-09
EA202190878A1 (ru) 2021-07-02
CA3112215A1 (en) 2020-04-09
MX2021003766A (es) 2021-05-27
BR112021005204A2 (pt) 2021-06-08
MY208925A (en) 2025-06-11
ECSP21031139A (es) 2021-06-30
PE20211213A1 (es) 2021-07-05
SG11202102875YA (en) 2021-04-29
PH12021550670A1 (en) 2022-01-03
KR20210074286A (ko) 2021-06-21
CN112804989A (zh) 2021-05-14
JP2024138284A (ja) 2024-10-08
US20220010020A1 (en) 2022-01-13
CO2021004985A2 (es) 2021-04-30
AU2019355995A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP2024138284A (ja) 抗ｆｇｆｒ２抗体製剤
US20220332826A1 (en) Humanized anti-human-pd-1 antibody
JP6860342B2 (ja) アフコシル化された抗ｆｇｆｒ２ｉｉｉｂ抗体
EP3399989B1 (en) Anti-lag3 antibodies and antigen-binding fragments
WO2022004760A1 (ja) 抗ｃｃｒ８抗体と化学療法剤の併用
JP7854782B2 (ja) Ｂ７－ｈ４抗体製剤
KR20240029119A (ko) 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
CN110621336A (zh) 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
US20230287123A1 (en) B7-h4 antibody dosing regimens
TW202345902A (zh) 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法
CN115006517A (zh) Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途
KR20250039373A (ko) 암 치료를 위한 결합 분자
EA049555B1 (ru) Составы на основе антитела к fgfr2
CN117545508A (zh) 用于癌的治疗和/或预防的药品
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40052955A (zh) 抗fgfr2抗体制剂
US20250084168A1 (en) Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof
HK40080422A (en) Il-21-anti-albumin single-domain antibody fusion protein pharmaceutical composition and use thereof
HK40033623A (en) Antibody binding to pd-1
CN114316046A (zh) 一种稳定的抗体组合物
HK40044506A (en) Afucosylated anti-fgfr2iiib antibodies

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220720

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241126

R150 Certificate of patent or registration of utility model

Ref document number: 7595567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150